Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;116(6):455-463.
doi: 10.14423/SMJ.0000000000001564.

STI Testing among Medicaid Enrollees Initiating PrEP for HIV Prevention in Six Southern States

Affiliations

STI Testing among Medicaid Enrollees Initiating PrEP for HIV Prevention in Six Southern States

Paul Lanier et al. South Med J. 2023 Jun.

Abstract

Objectives: The purpose of this study was to measure sexually transmitted infection (STI) testing among Medicaid enrollees initiating preexposure prophylaxis (PrEP) to prevent human immunodeficiency virus. Secondary data are in the form of Medicaid enrollment and claims data in six states in the US South.

Methods: Research partnerships in six states in the US South developed a distributed research network to accomplish study aims. Each state identified all first-time PrEP users in fiscal year 2017-2018 (combined N = 990) and measured the presence of STI testing for chlamydia, syphilis, and gonorrhea through 2019. Each state calculated the percentage of individuals with at least one STI test during 3-, 6-, and 12-month follow-up periods.

Results: The proportion of first-time PrEP users that received an STI test varied by state: 37% to 67% of all of the individuals in each state who initiated PrEP received a test within the first 6 months of PrEP treatment and 50% to 77% received a test within the first 12 months.

Conclusions: Although the Centers for Disease Control and Prevention recommends STI testing at least every 6 months for PrEP users, our analysis of Medicaid data suggests that STI testing occurs less frequently than recommended in populations at elevated risk of syphilis, gonorrhea, and chlamydia.

PubMed Disclaimer

Figures

Fig.
Fig.
Algorithm for identifying PrEP users combined for all states. HIV, human immunodeficiency virus; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; TDF-FTC, tenofovir disoproxil fumarate/emtricitabine.

References

    1. Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas 2019. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html. Published May 2021. Accessed February 26, 2023.
    1. US Department of Health and Human Services. HIV national strategic plan for the United States: a roadmap to end the epidemic 2021–2025. https://files.hiv.gov/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf. Published 2021. Accessed February 26, 2023.
    1. US Preventive Services Task Force; Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2203–2213. - PubMed
    1. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2214–2230. - PubMed
    1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019. https://www.cdc.gov/nchhstp/newsroom/2021/2019-std-surveillance-report-p.... Published 2021. Accessed February 26, 2023.

Publication types